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Background and Objective: The first pass effect (FPE; achieving complete
recanalization with a single thrombectomy device pass) has been shown to be associated
with higher rates of good clinical outcomes in patients with acute ischemic stroke. Here,
we investigate clinical and radiographic factors associated with FPE in a large U.S.
post-marketing registry (TRACK, Trevo Stent-Retriever Acute Stroke).
Methods: We analyzed the TRACK database (multicenter registry of 634 patients
from 23 centers from March 2013 through August 2015), which 609 patients were
included in the final analysis. FPE was defined as a single pass/use of device,
TICI 2c/3 recanalization, and no use of rescue therapy. Analysis of individual patient
data from TRACK were performed to analyze clinical and radiographic characteristics
associated with FPE as well-compared clinical outcomes defined as modified Rankin
Scale (mRS) score at 30 and 90 days from hospital discharge to the non-FPE group.
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Results: The rate of FPE in TRACK was 23% (140/609). There was no association
between patient demographics and FPE, including age (p = 0.36), sex (p = 0.50),
race (p = 0.50), location of occlusion (p = 0.26), baseline NIHSS (p = 0.62), or past
medical history. There was no difference in the use of a balloon-guide catheter or general
anesthesia (49 and 57% with FPE vs. 47 and 64%, p = 0.63 and p = 0.14, respectively).
Clinical outcomes were significantly associated with FPE; 63 vs. 44% in non-FPE patients
achieved mRS 0–2 at 90 days (p = 0.0004).
Conclusion: Our study showed that achieving complete recanalization with a single
thrombectomy pass using the Trevo device was highly beneficial. The most common
clinical factors that are used to determine eligibility for endovascular therapy, such as
NIHSS severity, location of occlusion or patient age were not predictive of the ability to
achieve FPE.
Keywords: stroke, Ischemia—reperfusion, endovascualar treatment, thrombectomy, brain
INTRODUCTION
Recanalization is a very powerful predictor of a good clinical
outcome in patients with acute ischemic stroke (AIS) from
emergent large vessel occlusion (ELVO) who are treated with
endovascular thrombectomy (ET). Analysis of angiographic
recanalization in the HERMES collaboration of pooled patient-
level data from seven trials (MR CLEAN, ESCAPE, REVASCAT,
SWIFT PRIME, EXTEND IA, THRACE, and PISTE) showed a
strong association of the benefit of endovascular therapy with the
degree of reperfusion achieved during ET (1). Recently, the first-
pass effect (FPE) defined as complete recanalization achieved
with a single thrombectomy device pass was described as a
novel metric of ET success (2). First described in the analysis
of the North American Solitaire Acute Stroke (NASA) Registry
database, FPE served as an independent predictor of good clinical
outcome after stent retriever thrombectomy (modified Rankin
Scale score 0–2 in 61% in FPE vs. 35% in non-FPE cohort; P
= 0.013) (2, 3). The benefit of FPE on clinical outcome was
subsequently confirmed by the Analysis of Revascularization
in Ischemic Stroke With EmboTrap (ARISE II) study of the
EmboTrap thrombectomy device (4).
Interestingly, stroke severity, patient age, location of ELVO
(except for the internal carotid artery [ICA] terminus clot
location), use of intravenous tPA and time of stroke symptom
onset to treatment were not predictive of FPE in NASA (2).
The analysis of the NASA registry did show that the use of a
balloon-guide catheter (BGC) was predictive of FPE. Similarly, a
separate prospective multicenter observational study of patients
with anterior circulation stroke treated with ET showed that the
use of BGC and stent retriever deployment maneuvers (standard
vs. “push and fluff” technique) were associated with FPE,
arguing that technical rather clinical variables affect procedural
outcomes (5).
Thus, it remains to be determined what baseline clinical
and radiographic characteristics of patients with ELVO
undergoing ET can predict FPE when treated with stent-retriever
thrombectomy as the primary treatment strategy. The TREVO
Stent-Retriever Acute Stroke (TRACK) Registry was an
investigator-initiated independent US post-marketing registry
that evaluated the real-life clinical experience of the Trevo device
in patients with AIS from ELVO (6). The registry demonstrated
the generalizability of the randomized endovascular stroke
thrombectomy clinical trials in real-world clinical practice,
including patients who were treated outside of the formal
American Heart Association clinical guidelines. The goal of
our study was to examine the clinical and radiographic factors
associated with FPE in the TRACK registry.
METHODS
The detailed description of the TRACK registry is provided in the
original manuscript (6). Institutional review board approval was
obtained at each site. Mercy Health St. Vincent Hospital (Toledo,
Ohio, USA) served as the coordinating center for TRACK.
Briefly, TRACKwas an operator-adjudicated multicenter registry
of 624 patients from 23 centers fromMarch 2013 through August
2015 with the aim to evaluate the use of the Trevo device
in clinical practice. The inclusion criteria included the Trevo
device as the first mechanical thrombectomy treatment method
to restore blood flow for ELVO and patients aged>18 years
old. Mercy Health St. Vincent Hospital (Toledo, Ohio, USA)
served as the coordinating center for TRACK. FPE is defined as a
single pass/use of device, TICI 2c/3 recanalization, and no use of
rescue therapy.
Demographic and clinical data analyzed in our study included
age, sex, race, medical history, occlusion location, pre-stroke
mRS, and treatment details including tPA administration, time
of onset to groin puncture, general anesthesia, and use of
rescue therapy. Final analysis included 609 patients compared to
original TRACK registry based on available patient demographic
and clinical data (n = 15 excluded). Angiographic recanalization
was defined using a modified Thrombolysis in Cerebral
Infarction (mTICI) score (7). Embolization into new territory
(ENT) and embolization of distal territory (EDT) were defined
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as treatment-related embolization into areas outside of target
downstream territory and any treatment-related embolization
into the target downstream territory, respectively (7). Clinical
outcomes were quantified using the National Institutes of Health
Stroke Scale (NIHSS) on discharge, and modified Rankin Scale
(mRS) score at 30 and 90 days from the day of hospital
discharge. A good clinical outcome was defined as mRS 0–
2. Symptomatic intracerebral hemorrhage (sICH) was defined
as any parenchymal hematoma, subarachnoid hemorrhage, or
intraventricular hemorrhage associated with worsening of the
NIHSS score by ≥4 points within 24 h.
Statistical Analysis
The TRACK registry was utilized to identify a FPE subgroup.
Baseline features including demographics and clinical data,
treatment details, and angiographic and clinical outcomes were
compared with the non-FPE patients. Statistical analyses were
performed using JMP V.13 (SAS institute, Cary, North Carolina,
USA). Chi square and Fisher exact were used for categorical
variables and the Student’s t-test/F-test for continuous variables.
For all statistical analyses, p-values were two-sided and p < 0.05
was considered statistically significant.
RESULTS
Six hundred and nine patients were included in the FPE vs.
non-FPE subgroup analysis from the TRACK registry.
The rate of FPE in TRACKwas 23% of patients (140/609). The
two groups had similar baseline demographics, including age (p
= 0.36), sex (p = 0.50), race (p = 0.50), and past medical history
(Table 1). There were no differences in baseline NIHSS in the
cohort in general and in a subgroup of patients with NIHSS<6
(p = 0.62 and p = 0.22, respectively). Pre-stroke mRS (p =
0.23), admission systolic and diastolic blood pressure (p = 0.58
and p = 0.77, respectively), location of occlusion (p = 0.26) and
mode of hospital arrival (p = 0.39) were also similar. The two
groups had equivalent rates of intravenous tPA administration
prior to thrombectomy with the Trevo device (p = 0.44), and
times of symptom onset to puncture including subgroups treated
within first 6 and 8 h of symptom onset (p = 0.84 and p =
0.90, respectively).
Median symptom onset to puncture time in minutes was not
significantly different between groups (268 and 285min, p =
0.32, Table 2). However, mean ± SD [median] procedural times
(groin puncture to final angiogram) was significantly shorter in
patients with FPE vs. non-FPE patients (49.6 ± 23.7 [47] min vs.
99.7 ± 53.9 [90] min, p < 0.0001, respectively). There was no
difference in the use of a balloon-guide catheter (49 vs. 47%; p =
0.63) or general anesthesia (57 vs. 64%; p = 0.14) with FPE vs.
non-FPE, respectively.
Clinical outcomes were significantly associated with FPE as
shown in Figure 1 and Table 3. The rates of good clinical
outcome in patients with FPE were higher at 30 days (46 vs. 32%
in non-FPE patients, p= 0.0069) and 90 days (63 vs. 44% in non-
FPE patients, p = 0.0004). Furthermore, NIHSS at discharge was
significant associated with group (FPE 9.1± 11.2 vs. non-FPE 12
± 11), p= 0.0004. The occurrence of EDTwas significantly lower
TABLE 1 | Baseline characteristics of patients with and without first pass effect
(FPE).
FPE
(N = 140)
Non-FPE
(N = 469)
P-value
Demographics and clinical data
Age (years), Mean ± SD, Median
[IQR]
65.3 ± 15.3,
66.5 [22.5]
66.5 ± 14.5,
69 [20.5]
0.36
Age > 80 years old, n (%) 26 (19) 84 (18) 0.90
Female sex, n (%) 72 (51) 224 (48) 0.50
Race, white, n (%) 92/139 (66) 321/463 (69) 0.50
Hypertension, n (%) 103 (74) 357 (76) 0.58
Atrial fibrillation, n (%) 57/139 (41) 179 (38) 0.55
Diabetes mellitus, n (%) 38 (27) 121 (26) 0.74
Hyperlipidemia, n (%) 76 (54) 229 (49) 0.29
Hx of smoking, n (%) 28 (20) 124/466 (27) 0.12
Coronary artery disease, n (%) 26/107 (24) 112/374 (30) 0.28
Systolic blood pressure (SBP) on
admission, Mean ± SD, Median
[IQR]
145 ± 25.9,
139 [31]
n = 139
145 ± 26.5,
145 [35.25]
n = 466
0.58
Diastolic blood pressure (DBP) on
admission, Mean ± SD, Median
[IQR]
78.4 ± 17.6,
78 [21]
n = 139
77.9 ± 19.2,
78 [24]
n = 460
0.77
Transfer, n (%) 65 (46) 239/468 (51) 0.39
NIHSS ≥ 6 130/138 (94) 453 (97) 0.22
Baseline NIHSS, Mean ± SD,
Median [IQR]
17.1 ± 6.9,
17 [9.25]
n = 138
17.4 ± 6.6,
17 [9]
0.62
Occlusion location n = 140 n = 468
MCA M1, n (%) 72 (51) 261 (56) 0.26
MCA M2, n (%) 18 (13) 61 (13)
MCA M3, n (%) 0 (0) 6 (1)
ACA, n (%) 2 (1.4) 3 (0.6)
ICA, n (%) 19 (14) 77 (16)
BA, n (%) 24 (17) 39 (8)
VA, n (%) 3 (2) 12 (3)
Extracranial carotid, n (%) 0 (0) 1 (0.2)
PCA, n (%) 1 (0.7) 3 (0.6)
Tandem, n (%) 1 (0.7) 5 (1)
Pre-stroke mRS n = 130 n = 431
mRS 0, n/N (%) 98 344 0.23
mRS 1, n/N (%) 10 43
mRS 2, n/N (%) 11 22
mRS 3, n/N (%) 8 12
mRS 4, n/N (%) 2 9
mRS 5, n/N (%) 1 1
Pre-stroke mRS 0-1, n/ N (%) 108/130 (83) 387/431 (90) 0.044
ACA, anterior cerebral artery; BA, basilar artery; ICA, internal carotid artery; IQR,
interquartile range; NIHSS, National Institutes of Health Stroke Scale; MCA, middle
cerebral artery; mRS, modified Rankin score; PCA, posterior cerebral artery; SD, standard
deviation; VA, vertebral artery. Rows that have mean and median values between groups,
p-values correspond to mean, SD values.
in the FPE group (1/104, 1%) compared to non-FPE (110/371,
30%), p < 0.0001. However, no association in ENT, sICH, or
death compared to FPE was present.
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TABLE 2 | Treatment details of patients with and without first pass effect (FPE).
FPE
(N = 140)
Non-FPE
(N = 469)
P-value
Treatment details
Intravenous tPA use, n/N (%) 66/138 (48) 241/467 (52) 0.44
TOG ≤ 6 h, n/N (%) 86/134 (64) 284/453 (63) 0.84
TOG ≤ 8 h, n/N (%) 106/134 (79) 362/453 (80) 0.90
TOG > 8 h, n/N (%) 28/134 (21) 91/453 (20) 0.90
Onset to puncture in minutes,
Mean ± SD, Median [IQR]
384.4 ± 352.9,
267.5 [245.25]
358.1 ± 234.8,
285 [244]
0.32
Total procedural time (Groin
puncture to final angiogram) in
minutes, Mean ± SD; Median
[IQR]
49.6 ± 23.7;
46.5 [26.5]
99.7 ± 53.9;
90 [69]
<0.0001
Total fluoroscopic time in
minutes, Mean ± SD, Median
[IQR]
18.5 ± 12.5,
14.6 [10.48]
36.3 ± 23.8,
30 [26]
<0.0001
Puncture to reperfusion in
minutes, Mean ± SD, Median
[IQR]
46.3 ± 27.4,
38 [25.75]
89.3 ± 51,
80 [63]
<0.0001
Use of BGC, n (%) 69 (49) 219 (47) 0.63
General anesthesia, n (%) 80 (57) 301 (64) 0.14
Use of rescue therapy, n/N (%) N/A 128/462 (28) –
# of passes, Mean ± SD, Median
[IQR]
N/A 2.2 ± 1.2,
2 [2]
–
BGC, balloon-guided catheter; IQR, interquartile range; TOG, time of onset to groin
puncture; tPA, tissue plasminogen activator. Rows that have mean and median values
between groups, p-values correspond to mean, SD values.
DISCUSSION
There is increasing evidence that achieving complete
recanalization with a single thrombectomy device pass in
patients with AIS from ELVO is highly beneficial. In our series
of patients treated with Trevo thrombectomy device as the
primary treatment strategy, 63% of patients with FPE achieved
a favorable clinical outcome at 3 months, in comparison to
44% of patients without FPE. This effect translates into a 43%
relative difference in achieving a good clinical outcome with
thrombectomy. While FPE is strongly associated with improved
clinical outcomes, our findings indicate the limitations of
current thrombectomy devices; only 23% of patients treated
with Trevo as the first line treatment achieved FPE. Comparable
findings were demonstrated in earlier studies, although with
some variations. For example, NASA analysis showed similar
rates of FPE achieved with Solitaire (only 25% of cases) (2). In
the ARISE II study, successful reperfusion within the first pass
achieved with the EmboTrap stent-retriever device was reported
52% (4). Using the mTICI 2c/3 definition of FPE, the rate of
reperfusion with EmboTrap was 40%. Furthermore, in ARISE
II, thrombectomy was limited to patients presenting with 8 h of
symptom onset whereas in NASA and TRACK patients were
treated within a longer time window, including wake-up strokes
(8). The current and prior studies strongly advocated toward
further innovation in thrombectomy devices, since more than
half of patients treated with stent retrievers currently do not
achieve FPE.
Interestingly, our study showed that themost common clinical
factors that are used to determine eligibility for endovascular
therapy, such as NIHSS severity, location of ELVO, symptom
onset to treatment or patient age were not predictive of the
ability to achieve FPE. Likewise, in NASA most clinical and
demographic factors such as stroke severity or the use of IV tPA
did not influence the success of FPE with an exception of the
presence of ICA occlusion, which was a negative independent
predictor of FPE (2).
Factors associated with thrombectomy failure are likely
multiple, including clot composition and burden, and
anatomical features such as increased vessel tortuosity,
according to prior investigation of factors associated with
stent retriever thrombectomy failure with patients with ELVO
(9–11). Unfortunately, the TRACK registry did not collect
information about clot characteristics such as clot density
or additional technical details, such as the length of the
Trevo device to determine how these factors may influence
FPE success. For example, in a single center analysis of
420 patients with ICA and MCA M1/2 occlusions treated
with Trevo and Solitaire, the use of longer stent retrievers
was found to be an independent predictor of FPE (12).
Similar outcomes were observed in a multi-center prospective
registry of patients treated with the Solitaire stent retriever
(STRATIS) (13).
An unexpected finding in our study was the lack of association
between the use of BGC and FPE (49% of cases with FPE and
47% of non-FPE cases utilized BGC in TRACK). By contrast in
NASA, BGC use was nearly twice as common in patients who
achieved FPE (64 vs. 35% in non-FPE patients) and its positive
effect was confirmed by a multivariate logistic regression analysis
(2). One possible explanation is that the use conjunct aspiration
with Trevo (14), may have influenced the effect of BGC. Because
of the limited data on the use of aspiration in conjunction
with Trevo captured in our registry (the use of that technique
with old generation 054 Penumbra catheter was just being
introduce into clinical practice when TRACKwas conducted), we
were not able to perform reliable statistical analysis to examine
such association. Further investigation regarding how BGC and
continuous aspiration affect FPE in patients with stent-retriever
thrombectomy is warranted.
The strengths of this study include the presented results
were obtained based on an operator-adjudicated analysis of
angiographic procedures, follow-up imaging studies, and the
data were collected in a prospective manner; however, our
study has limitations. The use of a Registry from 2013 to
2015 has inherent selection bias that may not be applicable to
patients treated with most recent generation of thrombectomy
devices. The information on important clot characteristics that
may influence FPE such as clot burden score, clot length
and the presence of hyperdense sign were not available. This
information can be collected by the neurointerventionalist from
baseline imaging, such as CT and CTA prior to beginning the
thrombectomy procedure and may guide how the procedure
is performed in order to achieve FPE. Several types of Trevo
devices were used in TRACK, the operators’ preference for
such devices were not detailed, and the database did not
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FIGURE 1 | Clinical outcomes in patients who achieved first-pass effect (FPE). Clinical outcomes measured with modified Rankin scale (mRS) at (A) 30 days and (B)
90 days show significantly higher rates of good clinical outcome (mRS 0-2) in patients in whom FPE was achieved in comparison to non-FPE patients (p = 0.0069
and p = 0.0004, respectively). Numbers indicated percentages of each mRS score achieved.
TABLE 3 | Outcomes in patients with and without first pass effect (FPE).
Variable FPE
(N = 138)
Non-FPE
(N = 459)
P-value
Clinical outcomes
mRS 0–2 at discharge, n/N(%) 38/100 (38) 83/338 (25) 0.0719
mRS 0–2 at 30 days, n/N(%) 25/54 (46) 53/165 (32) 0.0107
mRS 0–2 at 90 days, n/N(%) 77/122 (63) 177/398 (44) 0.0004
NIHSS at discharge, Mean ± SD 9.1 ± 11.2 12 ± 11 0.0004
NIHSS at 90 days, Mean ± SD 14.4 ± 18.5 19.2 ± 18.7 0.071
Death, n/N (%) 23/122 (19) 81/398 (20) 0.80
Angiographic outcomes
ENT, n/N (%) 4/95 (4) 16/334 (5) 0.99
EDT in same territory, n/N (%) 1/104 (1) 110/371 (30) <0.0001
sICH, n (%) 9 (7) 35 (8) 0.85
EDTL, embolization in distal territory; ENT, embolization in new territory; IQR, interquartile
range; NIHSS, National Institutes of Health Stroke Scale; mRS, modified Rankin score;
sICH, symptomatic intracerebral hemorrhage. Rows that have mean and median values
between groups, p-values correspond to mean, SD values.
include the information on device length/diameter used by
each operator.
CONCLUSIONS
Our study showed that achieving complete recanalization with
a single thrombectomy device pass using the Trevo device in
patients with AIS from ELVO is highly beneficial. However, the
finding that only 23% of patients treated with Trevo as the first
line treatment achieved FPE strongly advocated toward further
innovation in thrombectomy devices. The most common clinical
factors that are used to determine eligibility for endovascular
therapy, such as NIHSS severity, location of ELVO or patient age
were not predictive of the ability to achieve FPE. Further research
is needed to determine how clot morphology and treatment
details, including the use of BGC and conjunct aspiration, affect
FPE rates.
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